ArticleBritish journal of haematology2026

Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.

Maximilian Fleischmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.